Skip to main content
Fig. 7 | BMC Immunology

Fig. 7

From: Influenza virus-like particle vaccine containing both apical membrane antigen 1 and microneme-associated antigen proteins of Plasmodium berghei confers protection in mice

Fig. 7

Protective efficacy of VLPs. At 4 weeks after the 2nd boost immunization, naïve and immunized mice were challenge-infected with 0.5% of P. berghei by intraperitoneal route. Mice were monitored for 61 days following P. berghei infection to determine parasitemia, bodyweight changes, and survival rate. A significantly lower level of parasitemia was detected at 40 dpi from VLPs (AMA1 + MIC)-immunized mice (A, *P < 0.05). Also, VLPs (AMA1 + MIC)-immunized mice were partially protected from bodyweight reduction (B) and survived longer (13 days) than naïve challenge control (C)

Back to article page